New Drugs Offer Hope for Migraine Prevention
(Ivanhoe Newswire) –Two new studies offer hope for people with migraine. Both studies involve drugs that are aimed at preventing migraine from occurring, instead of stopping the attacks once they have started.
One study involved 163 people who had migraine from five to 14 days per month. They received either a placebo or a single IV dose of a drug called ALD403, and then they were followed for 24 weeks. Those who had the drug had an average of 5.6 migraine days a month, a 66 percent decrease, compared to 4.6 fewer days per month for those who received the placebo. Sixteen percent of those who received the drug had no migraine days at 12 weeks, while none of those who had the placebo were free from migraine at that point.
"These results may potentially represent a new era in preventive therapy for migraine," Peter Goadsby, MD, PhD, of the UC San Francisco and a member of the American Academy of Neurology, who is an author on both studies, was quoted as saying.
The other study involved 217 people who had migraines four to 14 days per month received biweekly subcutaneous injections of either a placebo or a drug called LY2951742 for 12 weeks. Those who received the drug had an average of 4.2 fewer migraine days per month at 12 weeks, or a 63-percent decrease, while those who received placebo had 3 fewer migraine days per month, or a 42-percent decrease.
For more information, go to: https://www.aan.com/PressRoom/Home/PressRelease/1271
SOURCE: American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 2014
Want to be the FIRST TO KNOW?
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.